Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
News
Fear itself: Unmasking the fight-or-flight response
So, what exactly happens inside your body when things go bump in the night?
New OMRF grant will focus on autoimmune condition
The project will focus on comparing certain immune cells in patients with Sjögren’s to those of healthy controls.
241 events raise $695,000 for OMRF research
Seventh annual concert and golf tournament benefit research
OMRF awarded two new grants to study lupus genes
Two grants will enable OMRF scientists to examine genes thought to play a role in lupus.
New findings cast light on lymphatic system, key player in human health
OMRF researchers have broken new ground in understanding how the lymphatic system works.
